Prior Art Litigation Search in Mexico City.

A prior art search Mexico City counsel relies on has to fit a system that surprises most foreign attorneys — because a Mexican patent fight is not decided in a civil court at all. At first instance, both infringement and invalidity (nullity) are heard and resolved by the Mexican Institute of Industrial Property (IMPI), an administrative authority in the capital, under the Federal Law for the Protection of Industrial Property (LFPPI) in force since 5 November 2020. Review runs to the Specialised IP Chamber of the Federal Court of Administrative Justice (TFJA), then by amparo to the federal courts. PerspireIP builds invalidity-grade searches for the accused parties challenging an asserted Mexican patent inside that administrative route.

Where a prior art search Mexico City case is actually decided

Mexico concentrates industrial-property disputes in one federal administrative body, not in the ordinary courts. A prior art search Mexico City counsel commissions is aimed at the Mexican Institute of Industrial Property (IMPI, Instituto Mexicano de la Propiedad Industrial), which is empowered to hear, conduct and resolve administrative proceedings for both patent infringement and invalidity, and to impose the corresponding sanctions. IMPI is seated in Mexico City, and because it is a national authority nearly every Mexican patent proceeding is filed and tried in the capital regardless of where the parties operate.

That single-forum design is the first thing to grasp. There is no regional patent court, no jury, and — unlike the United States or Europe — no civil trial judge deciding validity. The proceeding before IMPI is conducted much like a trial, on written pleadings and documentary evidence, but the decision-maker is an administrative examiner applying the LFPPI. Getting the prior art right at the IMPI stage matters enormously, because everything that follows is a review of the record built there.

• IMPI — first-instance administrative authority in Mexico City for infringement and nullity (invalidity)
• Specialised IP Chamber of the TFJA (SEPI) — reviews IMPI decisions through an annulment trial
• Federal circuit collegiate tribunals — hear the constitutional amparo against a TFJA judgment
• Supreme Court of Justice — only where a genuine constitutional question is at stake

IMPI, not a civil court: the administrative model foreign litigants miss

Attorneys used to the US district courts or the European civil-court and Unified Patent Court model routinely mis-scope a Mexican matter because they assume a judge decides validity. In Mexico, the same administrative authority that examined and granted the patent — IMPI — is also the body that later tests its validity in a nullity proceeding. Infringement enforcement and the nullity defence therefore live under one roof, and an accused infringer who wants to argue the patent is void raises it as a counterclaim when answering the infringement action.

The LFPPI, in force since 5 November 2020, modernised this framework. It kept IMPI’s exclusive administrative jurisdiction over infringement and invalidity, but it also let rights holders pursue damages through the civil courts without first exhausting the administrative remedy — a change from the old law, under which a firm IMPI infringement ruling was effectively a precondition to any damages claim. For an accused party, that means the validity of the asserted patent can be under attack at IMPI while a separate damages exposure is developing, and a strong invalidity search is the lever that neutralises both.

The practical consequence for a search is scope. Because IMPI is an examining office that tests novelty and inventive step on the merits, the invalidity record has to be built to the standard IMPI applies at grant — not the lighter touch of a non-examining registry. The strongest outcome is nearly always a documented piece of prior art the original examiner never had in front of them.

Grounds and windows: how nullity works under the 2020 LFPPI

A Mexican patent can be declared void on several grounds, and the deadline to bring a nullity action depends on which ground applies. The core grounds are that the subject matter is not an invention or is non-patentable, that it lacks novelty, inventive step or industrial application, that the patent was granted in contravention of the law in force at the time, or that it was granted through error or serious oversight, or to someone not entitled to it. The petitioner must show a direct and legitimate interest in challenging the patent.

• Not an invention / non-patentable subject matter — nullity can be sought at any time, with no limitation period
• Lack of novelty, inventive step or industrial application — the prior-art grounds; actionable at any time
• Granted in contravention of the applicable law — actionable at any time
• Granted through error, serious oversight or to a person not entitled — a five-year window running from publication of the grant in the Official Gazette

The takeaway for litigation counsel is that the most powerful attacks — lack of novelty and lack of inventive step — are not time-barred. A patent asserted years after grant can still be knocked out on prior art, so an accused party is rarely too late to build an invalidity case. What decides the outcome is the quality and dating of the references: whether each document can be proved to have been publicly available before the patent’s effective priority date, tested against the claim elements the way IMPI applies novelty and inventive step under the LFPPI.

Review by the TFJA Specialised IP Chamber, then amparo

An IMPI decision on infringement or invalidity is not the last word, but the path upward is administrative and then constitutional — not a fresh civil appeal. A party that loses at IMPI files an annulment trial before the Specialised IP Chamber (Sala Especializada en Materia de Propiedad Intelectual, or SEPI) of the Federal Court of Administrative Justice (TFJA), a dedicated bench of magistrates in Mexico City created specifically to handle patent, trademark and other IP disputes. The SEPI reviews whether IMPI’s ruling was lawful on the record before it.

A TFJA judgment can in turn be challenged by amparo — a constitutional appeal — before a federal circuit collegiate tribunal, where three magistrates examine whether the decision complies with constitutional guarantees. In the rare case that turns on the direct interpretation of a constitutional principle, the matter can reach the Supreme Court of Justice. The chain is long, but every stage above IMPI is a review of the evidentiary record; none of them is an opportunity to run a new trial or introduce a fresh search built from scratch.

That structure is exactly why the prior art has to be complete and correctly charted at the IMPI stage. If the decisive reference or the proof of its publication date is missing when IMPI decides, it is difficult to repair on review. We build the invalidity file so it stands up all the way through SEPI review and an amparo, with public-availability dating evidenced document by document.

Pharma and the IMPI–COFEPRIS linkage: Mexico City’s biggest patent fights

Mexico City hosts the corporate headquarters of nearly every major multinational pharmaceutical company operating in the country, and pharma is the single most litigated field in the Mexican patent system. Much of that conflict runs through the linkage system that ties patents to drug marketing authorisations. IMPI publishes a special edition of the Official Gazette — the Gazette for Medicaments (Gaceta) — roughly every six months, listing patents in force for allopathic drugs, much as the FDA’s Orange Book does in the United States, and COFEPRIS, the health regulator, is meant to consult it before clearing a generic.

The linkage system is a persistent battleground. Second-use and formulation patents are frequently contested, IMPI has historically rejected the listing of certain second-medical-use claims, and in March 2026 the government announced a new electronic IMPI–COFEPRIS linkage platform to make listings and consultation more transparent. For a generic or biosimilar applicant blocked by a listed patent, the durable answer is often to invalidate that patent on prior art — and pharmaceutical validity fights turn on a literature that reaches well beyond the patent databases.

• Journal articles, congress abstracts and posters that anticipate a compound, formulation or dosage claim
• Earlier patent families and their foreign equivalents, argued as novelty or obviousness references
• Pharmacopoeia entries, regulatory filings and clinical-trial disclosures with provable public dates
• Markush and selection-patent art, where an earlier genus can anticipate a later species claim

Consumer goods, telecoms and finance: the rest of the docket

Pharma is not the whole story. Mexico City is the country’s largest and wealthiest consumer market and a manufacturing base for cosmetics, personal-care, household and packaged-consumer goods, which generates a steady stream of patent and utility-model disputes over formulations, packaging, dispensers and mechanical devices. Utility-model registrations are common in this sector, and because they are examined more lightly than patents they are often vulnerable to a well-built novelty attack.

The capital is also Mexico’s telecommunications and financial hub. It is the seat of the major carriers and of a fast-growing fintech and banking sector, so assertions increasingly read on wireless, networking, payments and software subject-matter. That art often lives outside the patent record — in standards contributions, technical specifications, protocol drafts, product documentation and dated open-source repositories — and proving exactly when each disclosure became public is half the invalidity case. A prior art search Mexico City counsel relies on has to be scoped to the specific technology, because the decisive reference for a payments patent looks nothing like the reference that sinks a pharmaceutical claim.

One further point shapes every Mexican search: Mexico is a purely national system. There is no European-patent designation to attack and no regional court such as the UPC; foreign patent families reach Mexico through the PCT national phase or direct Paris Convention filings. That makes the Mexican patent, and the Mexican file wrapper, the specific target — while foreign counterparts of the same invention are frequently the richest source of anticipating art.

How PerspireIP builds a prior art search Mexico City case can rely on

Every engagement follows the same disciplined path. We map the asserted claims element by element, fix the effective priority date that actually governs each claim, and search against that date rather than the filing date on the cover. For pharma we run patent searching alongside deep non-patent retrieval — journals, congress abstracts, pharmacopoeia and regulatory disclosures — and for telecoms, fintech and consumer-goods matters we add standards, product and grey-literature searching, then build claim charts an IMPI examiner and the TFJA can follow.

• Claim charting mapped to novelty and inventive step as IMPI applies them under the LFPPI
• Deep retrieval across patent families, scientific and technical literature, standards records and product documentation
• Public-availability dating for every reference, evidenced so it survives SEPI review and amparo
• Prior art sized to your route — an IMPI nullity action, a counterclaim to an infringement suit, or a linkage-system challenge
• A written invalidity analysis and reference packages ready for IMPI, delivered to work with your Mexican counsel

We work alongside your Mexican litigation counsel as a specialist search partner, deliver to IMPI deadlines, and keep every engagement confidential. Whether you are a generic or biosimilar company facing a listed pharma patent, a consumer-goods manufacturer answering an infringement claim, or a telecoms or fintech defendant challenging an asserted patent, we scale to fit — a single search, a multi-patent campaign or ongoing support. Send us the patent number and your key dates, and we will scope a prior art search Mexico City project within one business day.

IP Landscape & Resources in Mexico City

Key intellectual-property authorities and venues relevant to Mexico City:

• IMPI (Instituto Mexicano de la Propiedad Industrial) — the Mexican patent office and the first-instance administrative authority that decides patent infringement and invalidity (nullity)
• Federal Court of Administrative Justice (TFJA) — its Specialised IP Chamber (SEPI) in Mexico City reviews IMPI decisions through an annulment trial
• COFEPRIS — the federal health regulator that operates the IMPI-COFEPRIS pharmaceutical linkage system with the Gazette for Medicaments
• WIPO — administers the PCT, the route through which most foreign patent families enter the national phase in Mexico

Request a Prior Art Search in Mexico City

Explore related PerspireIP services: Prior Art Litigation Search · Patent Invalidation · Patent Infringement Analysis.

Frequently Asked Questions